YEATS4: Key Regulator of Cell Growth and Disease (G8089)

Target Name: YEATS4

NCBI ID: G8089

YEATS4

YEATS4: Key Regulator of Cell Growth and Disease

YEATS4 (NUBI-1) is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a key regulator of cell growth and differentiation, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the defining features of YEATS4 is its ability to form a complex with a protein called NUBI-1. NUBI-1 is a transmembrane protein that is expressed in various tissues, including the brain, and is involved in the regulation of cell adhesion, migration, and survival. The interaction between YEATS4 and NUBI-1 has been shown to play a role in the regulation of cell proliferation, differentiation, and survival.

In addition to its role in cell signaling, YEATS4 is also thought to be involved in the regulation of inflammation. It has been shown to play a role in the regulation of immune cell function, and is implicated in the development of autoimmune diseases.

Given its complex role in cell signaling and inflammation, YEATS4 is a potential drug target. Researchers are currently working to develop small molecules that can inhibit the activity of YEATS4 and NUBI-1, with the goal of using these compounds to treat a variety of diseases. These efforts are supported by the fact that YEATS4 has been shown to play a role in the development of a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, YEATS4 is also of interest as a biomarker. Its expression has been shown to be altered in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that YEATS4 may be a useful biomarker for the diagnosis and treatment of these diseases.

Overall, YEATS4 is a protein that is of great interest to researchers because of its role in cell signaling and inflammation. Its potential as a drug target and biomarker make it an attractive target for further study.

Protein Name: YEATS Domain Containing 4

Functions: Chromatin reader component of the NuA4 histone acetyltransferase (HAT) complex, a complex involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A (PubMed:12963728, PubMed:14966270). Specifically recognizes and binds acylated histone H3, with a preference for histone H3 diacetylated at 'Lys-18' and 'Lys-27' (H3K18ac and H3K27ac) or histone H3 diacetylated at 'Lys-14' and 'Lys-27' (H3K14ac and H3K27ac) (PubMed:29437725, PubMed:30071723, PubMed:29900004). Also able to recognize and bind crotonylated histone H3 (PubMed:30071723). May also recognize and bind histone H3 succinylated at 'Lys-122' (H3K122succ); additional evidences are however required to confirm this result in vivo (PubMed:29463709). Plays a key role in histone variant H2AZ1/H2A.Z deposition into specific chromatin regions: recognizes and binds H3K14ac and H3K27ac on the promoters of actively transcribed genes and recruits NuA4-related complex to deposit H2AZ1/H2A.Z (PubMed:29437725). H2AZ1/H2A.Z deposition is required for maintenance of embryonic stem cell (By similarity)

The "YEATS4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YEATS4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets